Needs – Multiple topics in Hematology, on the diagnosis and treatment of cancers healthcare providers will see in practice. Review the agenda for specific topics.

Learning Objectives (ACCME, MOC, ANCC, ACPE) – Upon completion of this activity, the participant should be able to:

1. Modify current practice to improve patient outcomes by incorporating the most current therapies for hematologic malignancies.
2. Evaluate the best treatment options for newly diagnosed AML patients.
3. Identify the emerging therapies Myelodysplastic Syndromes and Acute Lymphoblastic Leukemias and discuss how to put these treatment options into practice.
4. Describe treatment options for managing patients with Chronic Myeloid Leukemia in the current landscape.
5. Identify the new treatment options for Myeloid and Lymphoblastic Leukemias and describe how to put these treatment options into practice.
6. Discuss the emerging treatment options for newly diagnosed with Multiple Myeloma and describe how to put these treatment options into practice.
7. Implement the emerging treatment approaches for patients with Relapsed / Refractory Multiple Myeloma and describe how to put these treatment options into practice.
8. Describe the most current treatment options for Waldenstrom’s Macroglobulinemia.
9. Adjust their diagnostic and treatment strategies for patients with Amyloidosis to include the latest options beyond Anti-CD38 Antibody therapy.
10. Implement current guidance for the diagnosis and treatment of patients with Complementopathies.
11. Discuss current treatment options for patients with Aplastic Anemia.
12. Describe best practices in the management of patients with classical bleeding and clotting disorders.
13. Identify the most effective cellular therapies needed to manage Sickle Cell Disease.
14. Treat Mantle Cell Lymphomas while navigating the current controversies in managing this disease.
15. Implement optimal treatment strategies for patients with Myeloproliferative Neoplasms in their practice.
16. Improve the management of patients with Chronic Lymphocytic Leukemia in their practice
17. Identify the emerging treatment options for Indolent Lymphoma and describe how to implement these treatment options in practice.
18. Explain how to effectively implement new therapies for Hodgkin Lymphoma.
19. Evaluate the best therapies for treating Aggressive B and T Cell Lymphomas.
20. Explain when to utilize cellular and Bispecific Antibody Therapy in the treatment of patients with Lymphoid Malignancies.
21. Describe how to implement Immune Effector therapies for patients with Multiple Myeloma.
22. Identify the optimal scenarios and timing to refer patients for Hematopoietic transplantation or cellular therapies.

SUCCESSFUL COMPLETION

In order to receive CE, all participants must attend the entire Symposium from 7:30 am – 7:20 pm. AND complete a Post-Evaluation.

Physician Accreditation Statement

This live activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Indy Hematology Education, Inc. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Purdue University College of Pharmacy designates this live activity for a maximum of 10 AMA PRA Category 1 Credit(s)™. Symposium – 7:30 am – 7:20 pm. Purdue University College of Pharmacy designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™ (Town Hall Interactive Meeting – 7:40 – 8:40 pm). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Part 2

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

PHARMACISTS

In order to receive CE, you must attend the entire Symposium from 7:30 am – 4:45 pm. Successful completion of this CME activity requires participants to complete a Post-Evaluation.

Pharmacists Accreditation Statement

Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/ equal opportunity institution. 

Symposium: 7:30 am – 4:45 pm.  Universal Activity Number (UAN): 0018-9999-21-001-L01-P This program is approved for 7.25 contact hours (0.725 CEU’s). 

Town Hall Interactive Meeting: 7:40 – 8:40 pm.  Universal Activity Number (UAN): 0018-9999-25-002-L01-P This program is approved for 1.0 contact hours (0.10 CEU’s).

NURSES

Successful completion of this CME activity requires participants attend the entire Symposium AND to complete a Post-Evaluation.

Nurses Accreditation Statement 

Purdue University Continuing Nursing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

The Symposium is approved for 7.25 contact hours (Symposium: 7:30 am – 4:45 pm).

The Town Hall Meeting is approved for 1.0 contact hours (Town Hall Interactive Meeting: 7:40 pm – 8:40 pm).

Faculty and Disclosure / Conflict of Interest Policy

To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships occurring within the past 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.

Disclosures will be provided prior to the start of the activity.

All relevant conflicts of interest will have been mitigated prior to the start of the activity.

None of the planners, reviewers, Indy Hematology Education, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.